Komori
Business Alliance4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Execution of an exclusive distribution agreement in Japan for the Rett syndrome treatment DAYBUE STIX (generic name: Trofinetide)

Kyorin Pharmaceutical entered into an agreement with Acadia Pharmaceuticals to acquire exclusive distribution rights in Japan for the Rett syndrome treatment DAYBUE STIX. Kyorin Pharmaceutical will pay an upfront payment of US$30 million and will subsequently file for regulatory approval and market the product.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
30
US$ million (upfront payment)
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliance
4569KYORIN Pharmaceutical Co.,Ltd.
Alliance partnerAcadia Pharmaceuticals Inc.
Details of the alliance
  1. 1

    We acquired the exclusive rights to market this product in Japan for the treatment of Rett syndrome.

  2. 2

    We will file the application for marketing approval.

  3. 3

    After the product is listed for reimbursement, we will receive product supplies from Acadia Pharmaceuticals and market the product exclusively.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Numerical targets under the alliance

Upon achieving certain net sales targets, we will pay up to US$45 million in milestone payments, among other amounts.

Capital and personnel relationships

This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).

Acquisition priceUpfront payment of US$30 million, plus up to US$45 million in milestone payments, among other amounts
About the partner
Business DescriptionDevelopment and marketing of treatments for neurological and rare diseases
LocationSan Diego, United States
Impact on Business Performance

Already reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2027. The upfront payment is scheduled to be recorded as selling, general and administrative expenses (research and development expenses) in the third quarter of the current fiscal year.

Alliance start dateExclusive marketing will begin after the product is listed for reimbursement. The specific date is Not disclosed
Agreements reached under this partnership
ItemDetails
Name of alliance partnerAcadia Pharmaceuticals Inc.
Alliance partner's business activitiesDevelopment and marketing of treatments for neurological and rare diseases
Alliance partner's locationSan Diego, United States
Type of allianceBusiness Alliance
Details of the allianceWe acquired the exclusive rights to market this product in Japan for the treatment of Rett syndrome., We will file the application for marketing approval., After the product is listed for reimbursement, we will receive product supplies from Acadia Pharmaceuticals and market the product exclusively.
Acquisition priceUpfront payment of US$30 million, plus up to US$45 million in milestone payments, among other amounts
Numerical targets under the allianceUpon achieving certain net sales targets, we will pay up to US$45 million in milestone payments, among other amounts.
Alliance start dateExclusive marketing will begin after the product is listed for reimbursement. The specific date is Not disclosed
Impact on Business PerformanceAlready reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2027. The upfront payment is scheduled to be recorded as selling, general and administrative expenses (research and development expenses) in the third quarter of the current fiscal year.
Items this document does not state (14)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide valuable new treatments that address unmet medical needs and make new treatment options available as soon as possible. The agreement will also advance the expansion of the development pipeline through proactive in-licensing investments, as set out in the medium-term management plan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Execution of an exclusive distribution agreement in Japan for the Rett syndrome treatment DAYBUE STIX (generic name: Trofinetide) | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori